Get started
Author

Audrey Muller

Observed names: A Muller, A. Muller, Muller, A, Muller, Audrey
ORCID: 0009-0008-9438-539X
Observed ORCID: 0009-0008-9438-539X
OpenAlex ID: A5002294585
Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review
2020 · Laurence Leber, Amélie Beaudet, et al. · Pulmonary Circulation · 263
PDF
Disease and patient characteristics in NP-C patients: findings from an international disease registry
2013 · Marc C Patterson, Eugen Mengel, et al. · Orphanet Journal of Rare Diseases · 201
PDF
A cohort study of interstitial lung diseases in central Denmark
2013 · Charlotte Hyldgaard, Ole Hilberg, et al. · Respiratory Medicine · 173
PDF
Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study
2015 · On behalf of the NPC Registry investigators, Marc C Patterson, et al. · Orphanet Journal of Rare Diseases · 98
PDF
Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study
2013 · P. Bauer, D. J. Balding, et al. · Human Molecular Genetics · 80
PDF
Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study
2013 · David J. Kuter, Atul Mehta, et al. · Blood Cells Molecules and Diseases · 70
Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE
2024 · Audrey Muller, Pilar Escribano-Subias, et al. · Advances in Therapy · 21
PDF
Evaluation of code‐based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases
2020 · Viviane P. Sprecher, Eva‐Maria Didden, et al. · Pulmonary Circulation · 21
PDF
Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
2022 · Pavel Jansa, David Ambrož, et al. · Pulmonary Circulation · 16
PDF
Results from a 9‐year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca®)‐treated patients
2015 · Monika Brand, Audrey Muller, et al. · Pharmacoepidemiology and Drug Safety · 16
Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSURE
2024 · Sean Gaine, Pilar Escribano‐Subias, et al. · Pulmonary Circulation · 14
PDF
Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)
2024 · Tobias J. Lange, Pilar Escribano-Subias, et al. · Advances in Therapy · 11
PDF
Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry
2013 · Marc C Patterson, Eugen Mengel, et al. · Orphanet Journal of Rare Diseases · 9
PDF
Association of risk assessment at diagnosis with healthcare resource utilization and health‐related quality of life outcomes in pulmonary arterial hypertension
2024 · Allan Lawrie, Neil Hamilton, et al. · Pulmonary Circulation · 7
Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service
2024 · David G Kiely, Neil Hamilton, et al. · BMJ Open · 7
PDF
Healthcare resource utilization and quality of life in patients with sarcoidosis‐associated pulmonary hypertension
2022 · Allan Lawrie, Neil Hamilton, et al. · Pulmonary Circulation · 5
PDF
Selexipag Experience in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Real-World Experience from EXPOSURE
2022 · S.P. Gaine, P. Escribano, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) in a Real-World Clinical Setting: Insights from the EXPOSURE Study
2021 · T.J. Lange, S. Söderberg, et al. · American Journal of Respiratory and Critical Care Medicine · 2
PDF
Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
2020 · Pavel Jansa, David Ambrož, et al. · European Respiratory Journal · 2
Survival in Pulmonary Arterial Hypertension (PAH) for 669 Patients Treated with Selexipag in Clinical Practice: Insights from EXPOSURE
2024 · S. Soderberg, P. Escribano Subias, et al. · The Journal of Heart and Lung Transplantation · 1
PDF
Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE
2022 · P Escribano, S Gaine, et al. · European Heart Journal · 1
Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE
2020 · Sean Gaine, Pilar Escribano, et al. · European Respiratory Journal · 1
Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study
2020 · T.J. Lange, P. Escribano, et al. · American Journal of Respiratory and Critical Care Medicine · 1
Pdg37 Real-world Use of Selexipag and Other Pulmonary Arterial Hypertension (pah) Therapies: an Observational Cohort Study in Patients With Pah (exposure)
2019 · A. Muller, S. Söderberg, et al. · Value in Health · 1
Longitudinal data from the international registry for Niemann-Pick disease type C (NPC)
2014 · Marc C. Patterson, Eugen Mengel, et al. · Molecular Genetics and Metabolism · 1
Works count: 44
Citation count: 1,025
H-index: 11
I10-index: 12
Year
Topic
Type